
International Conference on

Antimicrobial and Antibacterial Agents

Novembe19-20, 2018 | Bucharest, Romania



TENTATIVE PROGRAM

Conferences Series llc LTD

47 Churchfield Road
London W3 6AY, UK

Antimicrobial Congress 2018



EVENT PROGRAM

November 19, 2018

Opening Ceremony	08:30-09:00
Keynote Sessions	09:00-10:30
Panel Discussion	10:30-10:40
Antimicrobial Agents in Clinical Treatment	11:00-13:00
Lunch Break	13:00-14:00
Antimicrobial Pathogens : Alternative Approaches, Antimicrobial agents and novel vaccines	14:00-16:00
Workshop	16:00-18:00

Note: Event Program is subjected to change with final allotment of Speaker slots



EVENT PROGRAM

November 20, 2018

Keynote Sessions	09:00-10:30
Community acquired antimicrobial resistance: is it controllable?, Plant Based Vaccines, Antimicrobial therapy for gum disease Haematology & Immune System Diseases	11:00-13:00
Lunch Break	13:00-14:00
Plant Based Vaccines, Pediatric Infectious Disease`, Antibiotic resistance leads to increased mortality	14:00-15:30
Poster Presentations	16:00-17:00
Poster and Video Presentation	17:00-18:00

Note: Event Program is subjected to change with final allotment of Speaker slots



SCIENTIFIC SESSIONS

Antimicrobial Pathogens: Alternative Approaches

Antibiotic Therapy &
Antimicrobial Drugs
Antimicrobial Agents &
Chemotherapy
Antimicrobial Agents in Clinical Treatment
Pharmalogical Consideration of Infectious
Disease and Agents

Antimicrobial agents and novel vaccines

Global Antibacterial Drugs Market Key
Antimicrobial Textiles Market
Neuroinfectious Diseases
Molecular Epidemiology of
Neoplastic and Non-neoplastic disease
Plant Based Vaccines

Antimicrobiology in Epidemiology

Antimicrobial therapy for gum disease
Pediatric Infectious Disease
Antibiotic resistance leads to
increased mortality
Infection Diseases and Agents
Community acquired antimicrobial
resistance: is it controllable?



Organizing Committee Member

Pietro Mastroeni

Pietro Mastroeni received a Degree in Medicine and Surgery from the University of Messina, Italy. He moved to the University of Cambridge, UK where he completed his PhD before becoming a Research Fellow at Imperial College, University of London UK. He is currently a Reader in Infection and Immunity at the University of Cambridge, UK. In 2017 he was awarded the Higher Degree of Doctor of Science (ScD) st Cambridge and he is a Fellow of the Royal Society of Biology. He has published more than 120 papers in reputed journals, edited two books and he serves as an editorial board member for several international journals.

SESSION TALKS

Title:Why do bacteria persist beyond antibiotic treatment?
Peiro Mastroni, University of Cambridge, United Kingdom

Title: Engdevelopment Of Bio-Based Polymers Based On Agroforestry Waste Extractions Of Lignins Cured And Reinforced With Antimicrobial Agents Delaying Fungal And Bacterial Activity By Increasing The Period Of Life Of A Food On The Shelf
Luis Eduardo, Mexico

Title: High-level aminoglycoside resistance in the absence of 16S ribosomal RNA methyltransferase production among Gram-negative bacilli
Darini Ana Lucia, Brazil

Title: Flu Pathogenesis Proteolytic Theory And Its Role In The Improvement of Flu's Treatment
Valentina Divocha, Lugansk State Medical University, Rubezhnoe, Ukraine

Title:Microbiological and Physico-chemical Screening of Indian Honey
Padma Singh, Department of Microbiology, Gurukul Kangri University, India

Title: SCCmec and mecA in methicillin resistant staphylococci, a highly diversified element with new mutations in mecA
Ferhat DJOUDI, Algeria

Title: Persister phenotype diversity in P. aeruginosa populations from airways of patients with cystic fibrosis
Biljana Mojsoska, Denmark

Title: probability inspection using solution and ozone gas for lichen removal in historical levels for case study of perspolice pilot
Hossein Naderi, Iran

Title:Role of bacterial antioxidant defense in their resistance to bactericidal antibiotics
A C Matin, Professor of Microbiology and Immunology, Stanford University School of Medicine

Organizing Committee Member



Pierre A Morgon

Pierre A Morgon is CEO of MRGN Advisors and Regional Partner for Switzerland at Mérieux Développement. He is Chairman of the Board of Virometix, as well as Non-Executive Director to the Boards of Theradiag, of Eurocine Vaccines, and of Vaccitech. Pierre has over 30 years of experience in the global life science industry, especially with specialty care, vaccines and immunotherapy, at the helm of international operations, in C-level positions at global level in multinational corporations and as CEO of start-up companies. He is a lecturer in several MBA programs in world-class business schools and in life science conferences, and at the Mass Challenge biotechnology incubator in Switzerland.

SESSION TALKS

Title: Community-Acquired Methicillin-Resistant Staphylococcus aureus: characteristics epidemiology, clinical, microbiology and molecular biology ; SCCmec gene analysis and VISA in patients infected with Staphylococcus aureus and antibiotic resistance testing in 2 hospitals.

Latre Buntaran, Head of Microbiology Department Mayapada Hospitals, Indonesia

Title: Influence of sub-bactericidal concentrations of antiseptics on DNA and phenotypic markers of virulence of microorganisms

Anna G Afinogenova, St. Petersburg Pasteur Institute, Russia

Title: Let's quench the quorum; a novel approach to counter Quorum Sensing mechanism in the pathogenic Pseudomonas aeruginosa

Fazal Adnan, Pakistan

Title: Commonly use of Oral Antibiotics Resistance in Children Aged 1 to 12 Years with UTIs a Increasing Problem

Biswajit Batabyal, Research Scholar, OPJS University Churu, Rajasthan, India

Title: Panton valentine leukocidin (Luks PVL) producing methicillin resistant Staphylococcus aureus from health care centers in Tabuk City, Kingdom of Saudi Arabia

Bernard C Silvala, University of Tabuk, Tabuk City, Kingdom of Saudi Arabia



Venue

Bucharest, Romania















Contact: **Francis Bennett**
Tel: +1-201-380-5561; Ext: 7007
Email: antimicrobials@memeetings.net